Health
Rutgers leading a clinical trial assessing combination treatment for coronavirus – News-Medical.Net
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with…
Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections.
The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine…
-
Business22 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
Business24 hours agoWhy this investing expert is calling time on NAB shares
-
General21 hours agoFederal government funding extends cohealth GP services until July 2026
-
Noosa News19 hours agoSunshine Coast Airport receives green light for major upgrade opening doors to growth jobs and tourism across the region